Research Paper Volume 13, Issue 14 pp 18498—18514

Figure 4. M/T-Exo miRNA-205 inhibits breast cancer cells (BCCs) apoptosis via targeting E2F1. (A) The apoptotic level of M/T-Exo-cocultured BCCs treated with the negative control miRNA-205 inhibitor (NCi), miRNA-205 inhibitor (205i), or the combination of 205i and lentiviral vector carrying E2F1 (E2F1). (B) The protein expressions of cleaved caspase-9 and caspase-3 in M/T-Exo-cocultured BCCs treated with the negative control miRNA-205 inhibitor (NCi), miRNA-205 inhibitor (205i), or the combination of 205i and lentiviral vector carrying E2F1 (E2F1). (C) The apoptotic level of M/T-Exo-cocultured BCCs treated with DMSO or GW4869. (D) The protein expressions of cleaved caspase-9 and caspase-3 in M/T-Exo-cocultured BCCs treated with DMSO or GW4869. (E) The apoptotic level of M/T-Exo-cocultured BCCs treated with the negative control miRNA-205 inhibitor (NCi), miRNA-205 inhibitor (205i), or the combination of 205i and E2F1 siRNA (siE2F1). (F) The protein expressions of cleaved caspase-9 and caspase-3 in M/T-Exo-cocultured BCCs treated with the negative control miRNA-205 inhibitor (NCi), miRNA-205 inhibitor (205i), or the combination of 205i and E2F1 siRNA (siE2F1). Values are means ± SD. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001. At least three replicates were available for analysis in each treatment group.